Clinical Trials Logo

Nasopharyngeal Neoplasms clinical trials

View clinical trials related to Nasopharyngeal Neoplasms.

Filter by:
  • Recruiting  
  • « Prev · Page 12

NCT ID: NCT00364962 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients

Start date: April 2006
Phase: N/A
Study type: Observational

Investigate the treatment result of KTP laser nasopharyngectomy in recurrent NPC patients

NCT ID: NCT00363831 Recruiting - Clinical trials for Nasopharyngeal Neoplasms

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

Start date: July 2006
Phase: Phase 2
Study type: Interventional

Primary: - To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse. Secondary: - To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate. - To study the safety and tolerability of the regimen in patients with metastatic NPC.

NCT ID: NCT00304694 Recruiting - Clinical trials for Nasopharyngeal Cancer

Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

Start date: March 2006
Phase: N/A
Study type: Observational

18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

NCT ID: NCT00155181 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Molecular Mechanism of Nasopharyngeal Carcinoma

Start date: January 2005
Phase: N/A
Study type: Observational

EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses. Unlike other human herpes viruses, EBV can only predominately infect two types of human cells: lymphoid cells and epithelial cells and its infection is associated with several human malignancies of these two cell types. The lymphoid cancers associated with EBV infection include Burkitt’s lymphoma, Hodgkin’s disease, B lymphoma in immunodeficient patients and T/NK cell lymphoma. The carcinomas associated with EBV are nasopharyngeal carcinoma and gastric carcinoma. One unique biological feature of EBV is that it can infect and immortalize primary B lymphocytes in vitro into lymphoblastoid cell lines (LCL). So far, limited information is known about the whole EBV infection process and its regulation mechanism for immortalization. In this project, three EBV infection models are setting up to reveal the cellular events and signal transduction pathway possibly involved in EBV infection process and immortalization course of action.